Regeneron Pharmaceuticals Inc (REGN)

Quick ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash	US$ in thousands	2,488,200	2,011,800	1,920,700	2,602,000	2,730,000	2,152,300	1,937,200	3,916,300	3,105,900	3,491,300	3,395,100	3,345,700	2,885,600	3,432,400	2,072,200	1,437,900	2,193,700	1,573,000	1,992,200	2,208,200
Short-term investments	US$ in thousands	6,524,300	7,784,700	7,888,300	7,917,500	8,114,800	7,761,300	6,990,500	5,043,400	4,636,400	3,530,400	4,171,300	3,704,900	2,809,100	2,355,200	1,838,600	2,065,900	1,393,300	1,452,900	1,152,000	1,795,200
Receivables	US$ in thousands	6,211,900	6,107,100	5,717,100	5,222,200	5,667,300	5,584,500	5,121,300	5,118,600	5,328,700	5,548,300	5,161,400	4,839,000	6,036,500	5,452,000	6,998,600	4,173,000	3,111,500	3,553,300	2,380,200	2,531,400
Total current liabilities	US$ in thousands	3,944,300	3,661,000	3,508,600	3,580,900	3,423,400	3,598,600	3,104,400	3,100,100	3,141,300	2,879,200	3,033,900	3,007,600	3,932,500	3,714,800	3,732,400	3,217,800	2,697,400	2,337,800	3,702,400	2,055,200
Quick ratio		3.86	4.34	4.43	4.40	4.82	4.31	4.53	4.54	4.16	4.37	4.20	3.95	2.98	3.03	2.92	2.39	2.48	2.81	1.49	3.18

December 31, 2024 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,488,200K + $6,524,300K + $6,211,900K) ÷ $3,944,300K
= 3.86

The quick ratio of Regeneron Pharmaceuticals Inc has shown a consistently strong trend over the past few years. Starting at 3.18 on March 31, 2020, the ratio decreased to 1.49 by June 30, 2020, indicating a temporary liquidity strain. However, from September 30, 2020 onwards, the quick ratio improved significantly, reaching a peak of 4.82 on December 31, 2023. This suggests that the company has ample liquid assets to cover its short-term obligations.

The quick ratio remained relatively stable around the 4.0 mark in the most recent periods up to December 31, 2024, ranging from 3.86 to 4.43. This sustained high level of the quick ratio reflects Regeneron Pharmaceuticals' ability to meet its short-term liabilities with ease.

Overall, the trend in the quick ratio demonstrates the company's strong liquidity position and its ability to quickly convert its current assets into cash to meet immediate financial obligations.